Pause in Trading
Filed with ASX · · 1 page · English
Amplia Therapeutics Ltd. on 6ix
Earlier from Amplia Therapeutics
- Amplia Therapeutics to Present at the Life Sciences Investor Forum on March 12th
- Poster Presentation Demonstrating Combination Benefit of Narmafotinib in Preclinical Kras-Mutated Cancer Models
- Amplia Therapeutics Announces Opening of US Sites for Amplicity Pancreatic Cancer Trial
- Amplia Therapeutics - Quarterly Activities and Cash Flow Reports - December 2025
- Quarterly Activities/Appendix 4C Cash Flow Report
Later from Amplia Therapeutics
- Trading Halt
- Amplia Reports Improved Responses & Survival in ACCENT trial
- Amplia Therapeutics Reports Four Additional Complete Responses and Improved Overall Survival Data in Accent Pancreatic Cancer Trial
- Amplia Therapeutics Halts Recruitment in AMPLICITY Trial
- Accent Trial Mature Data Presented at International Conference
Follow Amplia Therapeutics into a list and get an email when it puts out news.
Follow Amplia Therapeutics